The second HIV treatment drug Complera has been accepted by the Food and Drug Administration. The medicine Complera is a combination of Truvada, which amalgamated the Emtriva and Viread and the non-nucleoside reverse transcriptase inhibitor Edurant.

The medicine Complera produced by the medicine manufacturing company Gilead Atripla received grant in 2006 from FDA and another single tablet, which comprised an amalgamation of four drugs called Quad is on its way to clinical trials. The medicine is not supposed to be recommended to every HIV-suffering patient. The doctors prescribe drugs in consideration to the health conditions of the HIV patients.

However, the single dose drug will make it easier for the patients to follow the medication prescribed by the doctors. Complera also comprises of some ill-effects like the other HIV drugs. The side effects of the medicine are lactic acidosis and severe liver damage. The medicine Complera is recommended to be taken once in a day by patients who have not been treated for HIV as yet.

The medicine will be manufactured by Gilead, who will be responsible for its marketing and availability along with the help of Tibotec in markets of various countries like the U. S., European Union, Canada, Brazil, Australia and New Zealand.